A Common DIO2 Polymorphism and Alzheimer Disease Dementia in African and European Americans

Elizabeth A. McAninch, Kumar Rajan, Denis A. Evans, Sungro Jo, Layal Chaker, Robin P. Peeters, David A. Bennett, Deborah C. Mash, Antonio C. Bianco

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Context: A common single nucleotide polymorphism in DIO2, Thr92AlaD2, has been associated with a transcriptome typically found in neurodegenerative diseases in postmortem human brain tissue. Objective: To determine whether Thr92AlaD2 is associated with incident Alzheimer disease (AD). Design: Population-based study; human brain tissue microarray. Setting: Community-based cohorts from Chicago and northeastern Illinois and religious clergymen from across the United States constituted the primary population. A representative sample of the U.S. population was used for secondary analyses. Participants: 3054 African Americans (AAs) and 9304 European Americans (EAs). Main Outcome Measure: Incident AD. Results: In the primary population, AAs with Thr92AlaD2 had 1.3 times [95% confidence interval (CI), 1.02 to 1.68; P = 0.048] greater odds of developing AD. AAs from a second population with Thr92AlaD2 showed a trend toward increased odds of dementia (odds ratio, 1.33; 95% CI, 0.99 to 1.78; P = 0.06) and 1.35 times greater odds of developing cognitive impairment not demented (CIND; 95% CI, 1.09 to 1.67; P = 0.006). Meta-analysis showed that AAs with Thr92AlaD2 had 1.3 times increased odds of developing AD/dementia (95% CI, 1.07 to 1.58; P = 0.008). In EAs, no association was found between Thr92AlaD2 and AD, dementia, or CIND. Microarray of AA brain tissue identified transcriptional patterns linked to AD pathogenesis. Conclusions: Thr92AlaD2 was associated with molecular markers known to underlie AD pathogenesis in AAs, translating to an observed phenotype of increased odds of developing AD/dementia in AAs in these populations. Thr92AlaD2 might represent one factor contributing to racial discrepancies in incident AD.

Original languageEnglish (US)
Pages (from-to)1818-1826
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume103
Issue number5
DOIs
StatePublished - May 1 2018
Externally publishedYes

Fingerprint

Polymorphism
African Americans
Alzheimer Disease
Brain
Confidence Intervals
Tissue
Microarrays
Population
Neurodegenerative diseases
Nucleotides
Transcriptome
Association reactions
Neurodegenerative Diseases
Single Nucleotide Polymorphism
Dementia
Meta-Analysis
Odds Ratio
Outcome Assessment (Health Care)
Phenotype

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

A Common DIO2 Polymorphism and Alzheimer Disease Dementia in African and European Americans. / McAninch, Elizabeth A.; Rajan, Kumar; Evans, Denis A.; Jo, Sungro; Chaker, Layal; Peeters, Robin P.; Bennett, David A.; Mash, Deborah C.; Bianco, Antonio C.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 103, No. 5, 01.05.2018, p. 1818-1826.

Research output: Contribution to journalArticle

McAninch, EA, Rajan, K, Evans, DA, Jo, S, Chaker, L, Peeters, RP, Bennett, DA, Mash, DC & Bianco, AC 2018, 'A Common DIO2 Polymorphism and Alzheimer Disease Dementia in African and European Americans', Journal of Clinical Endocrinology and Metabolism, vol. 103, no. 5, pp. 1818-1826. https://doi.org/10.1210/jc.2017-01196
McAninch, Elizabeth A. ; Rajan, Kumar ; Evans, Denis A. ; Jo, Sungro ; Chaker, Layal ; Peeters, Robin P. ; Bennett, David A. ; Mash, Deborah C. ; Bianco, Antonio C. / A Common DIO2 Polymorphism and Alzheimer Disease Dementia in African and European Americans. In: Journal of Clinical Endocrinology and Metabolism. 2018 ; Vol. 103, No. 5. pp. 1818-1826.
@article{348c4d392e644adbb56d0a6260836a54,
title = "A Common DIO2 Polymorphism and Alzheimer Disease Dementia in African and European Americans",
abstract = "Context: A common single nucleotide polymorphism in DIO2, Thr92AlaD2, has been associated with a transcriptome typically found in neurodegenerative diseases in postmortem human brain tissue. Objective: To determine whether Thr92AlaD2 is associated with incident Alzheimer disease (AD). Design: Population-based study; human brain tissue microarray. Setting: Community-based cohorts from Chicago and northeastern Illinois and religious clergymen from across the United States constituted the primary population. A representative sample of the U.S. population was used for secondary analyses. Participants: 3054 African Americans (AAs) and 9304 European Americans (EAs). Main Outcome Measure: Incident AD. Results: In the primary population, AAs with Thr92AlaD2 had 1.3 times [95{\%} confidence interval (CI), 1.02 to 1.68; P = 0.048] greater odds of developing AD. AAs from a second population with Thr92AlaD2 showed a trend toward increased odds of dementia (odds ratio, 1.33; 95{\%} CI, 0.99 to 1.78; P = 0.06) and 1.35 times greater odds of developing cognitive impairment not demented (CIND; 95{\%} CI, 1.09 to 1.67; P = 0.006). Meta-analysis showed that AAs with Thr92AlaD2 had 1.3 times increased odds of developing AD/dementia (95{\%} CI, 1.07 to 1.58; P = 0.008). In EAs, no association was found between Thr92AlaD2 and AD, dementia, or CIND. Microarray of AA brain tissue identified transcriptional patterns linked to AD pathogenesis. Conclusions: Thr92AlaD2 was associated with molecular markers known to underlie AD pathogenesis in AAs, translating to an observed phenotype of increased odds of developing AD/dementia in AAs in these populations. Thr92AlaD2 might represent one factor contributing to racial discrepancies in incident AD.",
author = "McAninch, {Elizabeth A.} and Kumar Rajan and Evans, {Denis A.} and Sungro Jo and Layal Chaker and Peeters, {Robin P.} and Bennett, {David A.} and Mash, {Deborah C.} and Bianco, {Antonio C.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1210/jc.2017-01196",
language = "English (US)",
volume = "103",
pages = "1818--1826",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - A Common DIO2 Polymorphism and Alzheimer Disease Dementia in African and European Americans

AU - McAninch, Elizabeth A.

AU - Rajan, Kumar

AU - Evans, Denis A.

AU - Jo, Sungro

AU - Chaker, Layal

AU - Peeters, Robin P.

AU - Bennett, David A.

AU - Mash, Deborah C.

AU - Bianco, Antonio C.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Context: A common single nucleotide polymorphism in DIO2, Thr92AlaD2, has been associated with a transcriptome typically found in neurodegenerative diseases in postmortem human brain tissue. Objective: To determine whether Thr92AlaD2 is associated with incident Alzheimer disease (AD). Design: Population-based study; human brain tissue microarray. Setting: Community-based cohorts from Chicago and northeastern Illinois and religious clergymen from across the United States constituted the primary population. A representative sample of the U.S. population was used for secondary analyses. Participants: 3054 African Americans (AAs) and 9304 European Americans (EAs). Main Outcome Measure: Incident AD. Results: In the primary population, AAs with Thr92AlaD2 had 1.3 times [95% confidence interval (CI), 1.02 to 1.68; P = 0.048] greater odds of developing AD. AAs from a second population with Thr92AlaD2 showed a trend toward increased odds of dementia (odds ratio, 1.33; 95% CI, 0.99 to 1.78; P = 0.06) and 1.35 times greater odds of developing cognitive impairment not demented (CIND; 95% CI, 1.09 to 1.67; P = 0.006). Meta-analysis showed that AAs with Thr92AlaD2 had 1.3 times increased odds of developing AD/dementia (95% CI, 1.07 to 1.58; P = 0.008). In EAs, no association was found between Thr92AlaD2 and AD, dementia, or CIND. Microarray of AA brain tissue identified transcriptional patterns linked to AD pathogenesis. Conclusions: Thr92AlaD2 was associated with molecular markers known to underlie AD pathogenesis in AAs, translating to an observed phenotype of increased odds of developing AD/dementia in AAs in these populations. Thr92AlaD2 might represent one factor contributing to racial discrepancies in incident AD.

AB - Context: A common single nucleotide polymorphism in DIO2, Thr92AlaD2, has been associated with a transcriptome typically found in neurodegenerative diseases in postmortem human brain tissue. Objective: To determine whether Thr92AlaD2 is associated with incident Alzheimer disease (AD). Design: Population-based study; human brain tissue microarray. Setting: Community-based cohorts from Chicago and northeastern Illinois and religious clergymen from across the United States constituted the primary population. A representative sample of the U.S. population was used for secondary analyses. Participants: 3054 African Americans (AAs) and 9304 European Americans (EAs). Main Outcome Measure: Incident AD. Results: In the primary population, AAs with Thr92AlaD2 had 1.3 times [95% confidence interval (CI), 1.02 to 1.68; P = 0.048] greater odds of developing AD. AAs from a second population with Thr92AlaD2 showed a trend toward increased odds of dementia (odds ratio, 1.33; 95% CI, 0.99 to 1.78; P = 0.06) and 1.35 times greater odds of developing cognitive impairment not demented (CIND; 95% CI, 1.09 to 1.67; P = 0.006). Meta-analysis showed that AAs with Thr92AlaD2 had 1.3 times increased odds of developing AD/dementia (95% CI, 1.07 to 1.58; P = 0.008). In EAs, no association was found between Thr92AlaD2 and AD, dementia, or CIND. Microarray of AA brain tissue identified transcriptional patterns linked to AD pathogenesis. Conclusions: Thr92AlaD2 was associated with molecular markers known to underlie AD pathogenesis in AAs, translating to an observed phenotype of increased odds of developing AD/dementia in AAs in these populations. Thr92AlaD2 might represent one factor contributing to racial discrepancies in incident AD.

UR - http://www.scopus.com/inward/record.url?scp=85047199083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047199083&partnerID=8YFLogxK

U2 - 10.1210/jc.2017-01196

DO - 10.1210/jc.2017-01196

M3 - Article

VL - 103

SP - 1818

EP - 1826

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -